financetom
Business
financetom
/
Business
/
XLCS Partners advises Sherwood Aviation on sale to HEICO Corporation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
XLCS Partners advises Sherwood Aviation on sale to HEICO Corporation
Apr 13, 2026 8:23 AM

NASHVILLE, Tenn., April 13, 2026 /PRNewswire/ -- XLCS Partners, Inc., a leading middle market investment bank, is pleased to announce that it served as exclusive M&A advisor to Sherwood Avionics and Accessories, Inc. ("Sherwood Aviation") on its acquisition by HEICO Corporation ( HEI ) through its Flight Support Group.

Founded in 1992 and headquartered near Miami's Opa-locka Airport in Florida, Sherwood Aviation is an FAA and EASA Part 145 repair station specializing in the maintenance, repair, and overhaul (MRO) of complex, mission-critical mechanical and electro-mechanical components for defense and select commercial aviation platforms. The company's capabilities span auxiliary power units (APUs), landing gear systems, wheels and brakes, pneumatics, hydraulics, fuel and lighting systems, avionics components, and related accessories. With a decades-long reputation for technical excellence and customer service, Sherwood Aviation has earned the trust of OEMs, government agencies, and operators around the world.

Under the terms of the transaction, HEICO ( HEI ) acquired 80% of Sherwood Aviation, with the balance of ownership continuing to be held by members of Sherwood Aviation's management team.

"This is a tremendous outcome for Sherwood Aviation, our team, and our customers. HEICO ( HEI ) is the ideal partner to support our next chapter of growth and OEM alliance while preserving everything we have built since 1992. The XLCS team was with us every step of the way, and we would recommend them without hesitation to any business owner considering a transaction," said Bryan Farrell, CEO of Sherwood Aviation.

"This transaction is a testament to what Sherwood Aviation has built over more than three decades," said Joe Contaldo, Partner and head of XLCS Aerospace & Defense. "Sherwood is exactly the kind of mission-critical, defense-focused MRO platform that the market's most sophisticated buyers recognize and pursue. We are proud and honored to have advised them on this milestone transaction and are thrilled with the outcome for the entire team."

XLCS acted as the exclusive M&A advisor to Sherwood Aviation, and the transaction was led by Joe Contaldo, Partner, and Reed McMahon, Vice President. The transaction was completed on April 6, 2026.

About XLCS Partners, Inc.

XLCS Partners is an investment banking firm providing M&A advisory services to select clients globally and is recognized for its vast experience advising owners of Aerospace & Defense businesses. More information is available at www.xlcspartners.com.

Media Contact: 

Kendra Span 

[email protected]

615-379-7783

View original content to download multimedia:https://www.prnewswire.com/news-releases/xlcs-partners-advises-sherwood-aviation-on-sale-to-heico-corporation-302740576.html

SOURCE XLCS Partners, Inc.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Apr 26, 2024
10:56 AM EDT, 04/26/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Friday it has signed a deal with Emtora Biosciences for the exclusive, global rights for eRapa, a phase 3-ready drug to treat familial adenomatous polyposis, an inherited condition that affects the gastrointestinal tract. Shares of the company rose more than 81% in recent Friday trading. The license...
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) AppFolio ( APPF ) shares were up more than 16% in recent trading on Friday, a day after the company posted stronger-than-expected Q1 earnings and raised 2024 revenue guidance. The company reported late Thursday it swung to Q1 adjusted earnings of $1.05...
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates to include recent stock movement in the headline and first paragraph.) ResMed ( RMD ) shares rose by more than 17% in recent Friday trading after the company reported fiscal Q3 non-GAAP earnings of $2.13 per diluted share, up from $1.68 a year earlier. Analysts surveyed by Capital IQ expected $1.91. Revenue...
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Apr 26, 2024
11:00 AM EDT, 04/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Friday it will submit a marketing authorization application to the European Medicines Agency for the teprotumumab medicine to treat moderate to severe thyroid eye disease in adults. Teprotumumab is approved for thyroid eye disease treatment in the US, Brazil and Saudi Arabia under the brand name Tepezza, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved